Zimmer Biomet Holdings financials
$91.62+0.64%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.18B | $2.09B | $2.24B | $2.00B | $2.08B | $1.91B | $2.02B | $1.82B | $1.94B | $1.89B | $1.94B | $1.75B |
| Gross profit | $1.54B | $1.51B | $1.45B | $1.44B | $1.49B | $1.36B | $1.44B | $1.29B | $1.39B | $1.38B | $1.40B | $1.24B |
| Gross margin | 70.8% | 72.4% | 64.7% | 72.1% | 71.5% | 71.2% | 71.0% | 70.5% | 71.5% | 72.9% | 72.2% | 70.4% |
| Operating income | $326.1M | $373.2M | $154.5M | $351.3M | $300.0M | $292.3M | $388.9M | $279.5M | $351.2M | $265.9M | $354.2M | $266.6M |
| Net income | $198.3M | $238.2M | $139.3M | $230.9M | $152.8M | $181.9M | $239.5M | $249.1M | $242.8M | $172.4M | $419.2M | $162.7M |
| Net margin | 9.1% | 11.4% | 6.2% | 11.5% | 7.4% | 9.5% | 11.8% | 13.7% | 12.5% | 9.1% | 21.6% | 9.3% |
| Diluted EPS | $1.03 | $1.22 | $0.70 | $1.16 | $0.77 | $0.91 | $1.20 | $1.23 | $1.18 | $0.84 | $2.01 | $0.77 |
| EBITDA | $626.7M | $649.5M | $544.8M | $656.3M | $589.3M | $582.7M | $673.4M | $562.6M | $635.9M | $628.9M | $420.8M | $539.4M |
| Operating cash flow | $447.9M | $359.2M | $517.3M | $418.8M | $378.3M | $382.7M | $506.2M | $395.8M | $369.4M | $228.0M | $588.4M | $337.6M |
| Free cash flow | $347.3M | $206.7M | $368.2M | $137.6M | $250.1M | $276.0M | $402.8M | $162.9M | $340.1M | $90.9M | $446.7M | $188.8M |
| Diluted shares | 192.8M | 195.8M | 198.0M | 198.8M | 198.3M | 199.7M | 200.0M | 203.0M | 206.4M | 206.2M | 208.5M | 210.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $410.0M | $424.2M | $591.9M | $1.29B | $556.9M | $1.38B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $7.48B | $7.47B | $7.52B | $8.11B | $7.57B | $7.18B |
| Total assets | $22.80B | $22.72B | $23.09B | $23.49B | $22.87B | $22.18B |
| Total liabilities | $10.17B | $10.04B | $10.39B | $10.72B | $10.33B | $9.78B |
| Shareholders' equity | $12.63B | $12.68B | $12.71B | $12.77B | $12.53B | $12.40B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology